Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the
Fischer Imaging will remain listed on the Nasdaq exchange at least until Nov. 14, at which time the company must have filed necessary documentation or face delisting. In order to remain on the exchange, Fischer must complete an amended Form 10-Q for the quarter ended June 30, 2002, including an affirmative disclosure that the report has been reviewed consistent with SAS 71, as well as a Form 10-Q for the quarter ended Sept. 30, 2002. Alliance Pharmaceutical had no such recourse. The company announced Oct. 17 its delisting from the exchange for failure to meet certain requirements. The company¹s stock is now being traded on Nasdaq's over-the-counter bulletin board.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.